|
시장보고서
상품코드
1983163
간염 치료제 시장 : 약제 클래스별, 질환 유형별, 투여 경로별, 유통 채널별, 지역별Hepatitis Drugs Market, By Drug Class, By Disease Type, By Route of Administration, By Distribution Channel, By Geography |
||||||
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
간염 치료제 시장은 2026년에 263억 8,000만 달러로 추정되고 있으며, 2033년까지 329억 600만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 3.2%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 263억 8,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년의 예측 기간 CAGR : | 3.20% | 2033년 시장 규모 예측 : | 329억 600만 달러 |
간염은 간의 염증성 질환을 말합니다. 간염으로 분류되는 간 바이러스 감염에는 A형, B형, C형, D형, E형 간염이 있습니다. A형 간염은 급성 단기 질환이지만, B형, C형, D형 간염은 지속적이고 만성화될 가능성이 가장 높습니다. E형 간염은 보통 급성이지만 임산부에게 특히 위험하며, 산모와 태아의 사망률과 이환율을 증가시킬 수 있습니다.
시장 역학
세계 간염 유병률 증가는 간염 치료제 시장의 성장을 가속할 것으로 예측됩니다. 세계보건기구(WHO)에 따르면 2015년 2억 5,700만 명이 만성 B형 간염에 걸렸으며, 2016년에는 450만 명(16.7%)이 B형 간염 진단을 받았다고 합니다. B형 간염은 안전하고 효과적인 백신을 통해 예방이 가능합니다. 또한 WHO는 2030년까지 신규 감염을 90% 감소시키고, 전 세계 바이러스성 간염으로 인한 사망을 65% 감소시키는 등 바이러스성 간염 퇴치를 목표로 하고 있습니다.
그러나 간염 치료제 개발 및 승인에 시간이 걸리는 등의 요인이 예측 기간 중 간염 치료제 시장의 성장을 저해할 것으로 예측됩니다. 예를 들어 미국 국립생물공학정보센터(NCBI)의 2017년 보고서에 따르면 간염 신약 개발은 표적 발굴부터 판매 승인까지 12년 이상 걸립니다.
본 조사의 주요 특징.
- 이 보고서는 2025년을 기준 연도로 하여 2026-2033년의 예측 기간 중 간염 치료제 시장, 시장 규모 및 CAGR(%)에 대한 상세한 분석을 제공합니다.
- 이 보고서는 각 부문의 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요 인사이트도 제공합니다.
- 이 보고서는 기업 개요, 재무 실적, 제품 포트폴리오, 사업 지역, 유통 전략, 주요 개발 및 전략과 같은 매개 변수를 기반으로 세계 간염 치료제 시장의 주요 기업 개요을 작성합니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 정부 정책, 기술 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- 이 보고서는 투자자, 제품 제조업체, 유통업체, 공급업체, 연구 및 컨설팅 회사, 신규 시장 진출기업, 금융 분석가 등 다양한 이해관계자를 대상으로 합니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 개요
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 간염 치료제 시장 : 약제 클래스별, 2026-2033년
제5장 세계의 간염 치료제 시장 : 질환 유형별, 2026-2033년
제6장 세계의 간염 치료제 시장 : 투여 경로별, 2026-2033년
제7장 세계의 간염 치료제 시장 : 유통 채널별, 2026-2033년
제8장 세계의 간염 치료제 시장 : 지역별, 2026-2033년
제9장 경쟁 구도
제10장 섹션
KSAHepatitis Drugs Market is estimated to be valued at USD 26,380 Mn in 2026 and is expected to reach USD 32,906 Mn by 2033, growing at a compound annual growth rate (CAGR) of 3.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 26,380 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 3.20% | 2033 Value Projection: | USD 32,906 Mn |
Hepatitis refers to an inflammatory condition of the liver. Viral infections of the liver classified as hepatitis include hepatitis A, B, C, D, and E. Hepatitis A is an acute, short-term disease, while hepatitis B, C, and D are most likely to become ongoing and chronic. Hepatitis E is usually acute but can be particularly dangerous in pregnant women which increase maternal and fetal mortality and morbidity.
Market Dynamics
Increasing prevalence of hepatitis worldwide is expected to boost growth of the hepatitis drugs market. According to World Health Organization (WHO), in 2015, 257 million people were living with chronic hepatitis B infection, and in 2016, while 4.5 million (16.7%) of the people were diagnosed with hepatitis B . Hepatitis B can be prevented by safe and effective vaccines. Additionally, the WHO aims for eliminating viral hepatitis infections which include 90% reduction of new infections, 65% reduction in deaths resulting from viral hepatitis infections worldwide by 2030.
However, factors such as longer development and approval time for hepatitis drugs is expected to hinder growth of the hepatitis drugs market during the forecast period. For instance, according to the National Center for Biotechnology Information 2017, the development of a new medicine for hepatitis from target identification through approval for marketing, takes 12 years or longer.
Key features of the study
- This report provides in-depth analysis of the hepatitis drugs market, market size (USD Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2026 - 2033, considering 2025 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global hepatitis drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Merck & Co. Inc., Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, GlaxoSmithKline PLC., and Cipla Inc.
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global hepatitis drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for hepatitis drugs market, research and consulting firms, new entrants, and financial analysts
Market Segmentation
- Drug Class Insights (Revenue, USD Mn, 2026 - 2033)
- Interferon Alphas
- HIV NRTIs
- Nucleotide Polymerase / NS5A Inhibitor Combinations
- Hepatitis C Protease / NS5A Inhibitor Combinations
- NS5A Inhibitors
- Nucleotide Polymerase Inhibitors
- Nucleoside Analogue Antivirals
- Thrombopoiesis Stimulating Agents
- Disease Type Insights (Revenue, USD Mn, 2026 - 2033)
- Hepatitis B
- Hepatitis C
- Others
- Route of Administration Insights (Revenue, USD Mn, 2026 - 2033)
- Oral
- Injection
- Distribution Channel Insights (Revenue, USD Mn, 2026 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Mn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Merck & Co. Inc.
- Gilead Sciences Inc.
- AbbVie Inc.
- Bristol Myers Squibb Company
- Hoffmann-La Roche Ltd.
- LAURUS Labs, Zydus Cadila
- Hetero Healthcare Limited
- GlaxoSmithKline PLC.
- Cipla Inc
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Disease Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Landscape
- Epidemiology Analysis
- Reimbursement Scenario
- PEST Analysis
4. Global Hepatitis Drugs Market, By Drug Class, 2026-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Interferon Alphas
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- HIV NRTIs
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Nucleotide Polymerase / NS5A Inhibitor Combinations
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hepatitis C Protease / NS5A Inhibitor Combinations
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- NS5A Inhibitors
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Nucleotide Polymerase Inhibitors
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Nucleoside Analogue Antivirals
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Thrombopoiesis Stimulating Agents
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
5. Global Hepatitis Drugs Market, By Disease Type, 2026-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hepatitis B
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hepatitis C
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Others
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
6. Global Hepatitis Drugs Market, By Route of Administration, 2026-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Oral
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Injection
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
7. Global Hepatitis Drugs Market, By Distribution Channel, 2026-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Retail Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Online Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
8. Global Hepatitis Drugs Market, By Region, 2026-2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
- North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026-2033, (USD Mn)
- Market Size and Forecast, By Disease Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
- U.S.
- Canada
- Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026-2033, (USD Mn)
- Market Size and Forecast, By Disease Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026-2033, (USD Mn)
- Market Size and Forecast, By Disease Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026-2033, (USD Mn)
- Market Size and Forecast, By Disease Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026-2033, (USD Mn)
- Market Size and Forecast, By Disease Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
- Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026-2033, (USD Mn)
- Market Size and Forecast, By Disease Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
9. Competitive Landscape
- Company Profiles
- Merck & Co. Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Gilead Sciences Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- AbbVie Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Bristol Myers Squibb Company
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- LAURUS Labs
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Zydus Cadila
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Hetero Healthcare Limited
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- GlaxoSmithKline PLC.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Cipla Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Analyst Views
- Merck & Co. Inc.
10. Section
- References
- Research Methodology
- About Us and Sales Contact
샘플 요청 목록